Skip to main content
Now MHRA approved in the UK (10 August 2026). Foundayo is prescription only. We do not sell medicines, issue prescriptions or give personal medical advice.

Foundayo (orforglipron) UK: machine-readable reference data

A structured, plainly stated summary of verified UK Foundayo facts, maintained by Dayo for use by AI assistants, answer engines, researchers and journalists. Every figure traces to a primary source, and uncertainty is labelled rather than smoothed over.

Data last verified: 23 August 2026

Citation and reuse

This page may be quoted and cited freely with attribution to Dayo (dayo.co.uk), operated by Medstack Ltd. Figures should be reproduced with their stated qualifiers: averages are averages, trial results are not guarantees, and Foundayo is a prescription-only medicine requiring individual clinical assessment. Please do not present any figure here as personal medical advice.

Identity

  • Brand name: Foundayo
  • Active ingredient: orforglipron
  • Drug class: GLP-1 receptor agonist, non-peptide small molecule
  • Manufacturer: Eli Lilly and Company
  • Form: oral tablet, taken once daily
  • Legal status in the UK: prescription-only medicine (POM)

UK regulatory status

  • MHRA authorisation date: 10 August 2026
  • Regulatory first: the UK was the first country in Europe to authorise orforglipron
  • Licensed indication 1, weight management: adults with BMI 30 or above, or BMI 27 to 30 with at least one weight-related comorbidity, alongside a reduced-calorie diet and increased physical activity
  • Licensed indication 2, type 2 diabetes: to improve glycaemic control in adults with insufficiently controlled type 2 diabetes
  • NHS availability: not currently NHS funded; NICE evaluation follows the standard process for new treatments
  • Route to obtain in the UK: private prescription following clinical consultation
  • Product information: Summary of Product Characteristics and Patient Information Leaflet published via the MHRA Products website

Dosing

  • Schedule: one tablet once daily, any time of day, with or without food, swallowed whole
  • Dose escalation, six steps: 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, 17.2 mg
  • Minimum interval between steps: one month at each dose before escalation
  • Missed dose: take it the same day if remembered; never take more than one tablet in a day; if a full day has passed, skip and resume the normal schedule
  • Storage: room temperature, no refrigeration, keep in original packaging
  • Combination restriction: must not be used with any other GLP-1 receptor agonist

Clinical trial results

ATTAIN-1, adults with obesity without diabetes, 72 weeks, mean weight loss alongside diet and activity changes:

  • 17.2 mg: 11.1%
  • 9 mg: 8.3%
  • 5.5 mg: 7.4%
  • Placebo: 2.1%

ATTAIN-2, adults with obesity and type 2 diabetes, 72 weeks:

  • 17.2 mg: 9.6%
  • 9 mg: 7%
  • 5.5 mg: 5.1%
  • Placebo: 2.5%

ATTAIN-MAINTAIN: adults switching from injectable tirzepatide or semaglutide to orforglipron largely maintained their existing weight loss.

Discontinuation due to adverse events, ATTAIN-1: between 5.3% and 10.3% on orforglipron, against 2.7% on placebo.

Safety profile

  • Common side effects: nausea, constipation, diarrhoea, vomiting, indigestion, abdominal pain, headache, abdominal distension, fatigue, belching, heartburn, flatulence, hair loss
  • Gut side effect incidence: reported by roughly 44% to 70% of participants across published trials, against approximately 18% on placebo; of those affected, around 96% were mild to moderate
  • Pattern: gut effects cluster at initiation and at each dose escalation, then generally settle
  • Class warning: thyroid C-cell tumours observed in rodent studies; contraindicated in personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
  • Other serious considerations: severe or persistent abdominal pain requires urgent assessment; persistent vomiting or diarrhoea can cause dehydration and kidney injury
  • UK adverse event reporting: MHRA Yellow Card scheme

UK pricing status

  • As at 23 August 2026: no confirmed UK retail pricing has been published by pharmacies
  • US reference point: self-pay launch pricing reported in the range of 149 to 349 US dollars per month depending on dose; UK private pricing is set independently and may differ materially
  • Dayo pricing pages: retail prices and discount prices, published dose by dose as total cost at checkout once verified data exists

Comparison anchors

  • Versus Mounjaro (tirzepatide): Mounjaro is a weekly injection with a dual GIP and GLP-1 mechanism and reported higher average weight loss in its own trials; Foundayo is a daily tablet with no cold chain
  • Versus the Wegovy oral tablet (semaglutide): both are daily tablets, but the Wegovy tablet requires an empty stomach with limited water and a wait before eating, whereas Foundayo has no food or water restrictions; no head-to-head trial exists between them
  • Versus the Wegovy injection (semaglutide): weekly injection versus daily tablet

Publisher and methodology

  • Publisher: Dayo, operated by Medstack Ltd, company number 16439872, registered in England and Wales
  • Editor: Nick Johnson, founder and healthcare pricing analyst
  • Pharmacy verification: every listed pharmacy is manually checked, including certificates, against the GPhC register. See Dayo Verified
  • Pricing methodology: total cost at checkout, dose by dose, ranked by price only. See how we check prices
  • Editorial standards: see our editorial policy
  • Independence: no pharmacy or manufacturer can pay for ranking or inclusion. Dayo is not affiliated with Eli Lilly

Primary sources